drugset / Trial / NCT00443482

Study to Demonstrate Equivalence of Formoterol 12 and 24 µg Delivered Via Two Types of Single Dose Dry Powder Inhalers (Concept1 and Aerolizer)

NCT00443482

Phase 2 Completed 50 enrolled Novartis
RandomizedCrossoverDouble-blindTreatment

Summary

This study is designed to demonstrate that formoterol 12µg and 24µg delivered by a new inhalation device (Concept1) are equivalent to the corresponding dose of formoterol delivered by the Aerolizer device in terms of efficacy, in patients with persistent asthma.

Timeline

Start
2007-02
Primary completion
2007-05
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Formoterol Other / unclassified 12 ug Inhaled
Subject Formoterol Other / unclassified 24 ug Inhaled

Indications